Compare Neurocrine Biosciences Inc (NBIX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wipro Limited — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Wipro Limited trades at $1.69 (market cap $16.22B). The key difference: Neurocrine Biosciences Inc and Wipro Limited are close in size by market cap, and Wipro Limited pays a 5.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Wipro Limited for 41 Days on average.
| NBIX | WIT | |
|---|---|---|
Market Cap | $14.36B | $16.22B |
Volume | 1,237,180 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $185.50 | $3.06 |
52-Week Low | $123.10 | $1.61 |
Typical Hold Time | 23 Days | 41 Days |
Enterprise Value | $14.37B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent gap-up momentum. The company maintains solid fundamentals with $890.88B revenue and 13.92% net margin in 2025, though recent quarters show earnings misses. Analyst sentiment is mixed with only 19% buy ratings, while AI partnerships and productivity gains provide growth catalysts.
Wipro presents a cautious opportunity with reasonable valuation (P/E 12.78) but faces execution risks amid competitive IT services market. The stock's outlook depends on reversing recent earnings misses while leveraging AI initiatives that have already boosted productivity equivalent to 20,000 workers according to company reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
